Isabel Nicolas de Prado
Overview
Explore the profile of Isabel Nicolas de Prado including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giordano A, Perez-Martinez I, Gisbert J, Ricart E, Martin-Arranz M, Mesonero F, et al.
Am J Gastroenterol
. 2025 Jan;
120(1):194-203.
PMID: 39745305
Introduction: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between...
2.
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, de Prado I, Bernal Morell E, Rentero Redondo L
Gastroenterol Hepatol
. 2023 Aug;
47(6):553-561.
PMID: 37597745
Background: Studies have investigated the efficacy and safety of switching to the biosimilar infliximab (CT-P13) in patients with inflammatory bowel disease (IBD). However, there is limited research directly comparing the...
3.
Serrano Diaz L, Iniesta Navalon C, Gomez Espin R, de Prado I, Rentero Redondo L
Gastroenterol Hepatol
. 2022 Nov;
46(7):504-511.
PMID: 36400260
Background And Objectives: There is increasing evidence that proactive monitoring is useful in improving the control of inflammatory bowel disease, although it remains controversial. The aim of this study was...
4.
Iniesta Navalon C, Gil Candel M, Salar Valverde I, de Prado I, Gomez Espin R, Rentero Redondo L
Rev Esp Enferm Dig
. 2021 Jan;
113(11):770-775.
PMID: 33486961
Background: efficacy and safety were evaluated after switching to a biosimilar infliximab (CPT-13) in patients with inflammatory bowel disease (IBD). However, few cohort studies compare the pharmacokinetic profiles, immunogenicity, and...
5.
Gomez Espin R, de Prado I, Gil Candel M, Gonzalez Carrion M, Rentero Redondo L, Iniesta Navalon C
Rev Esp Enferm Dig
. 2020 Nov;
113(2):110-115.
PMID: 33213170
Introduction: numerous studies have shown a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes during the induction and maintenance period in patients with Crohn's disease (CD). To...
6.
Sanchez J, Serrano Diaz L, Chuni Jimenez D, Ruiz Moreno M, Gallego Perez B, Marin Bernabe C, et al.
Rev Esp Enferm Dig
. 2020 Oct;
112(11):854-859.
PMID: 33054303
Introduction: informed consent is necessary for invasive procedures as a document that guarantees the ethical health relationship and patient safety. Aims: to analyze whether we have and use informed consent...
7.
Gil Candel M, Gascon Canovas J, Gomez Espin R, de Prado I, Rentero Redondo L, Sanz E, et al.
Rev Esp Enferm Dig
. 2020 Jul;
112(8):590-597.
PMID: 32686429
Introduction: infliximab is used in inflammatory bowel disease, which has a great inter-individual pharmacokinetic variability. Thus, it is necessary to individualize the therapy in many cases. The main objective of...
8.
Gil Candel M, Gascon Canovas J, Sanz E, Gomez Espin R, de Prado I, Iniesta Navalon C
Rev Esp Enferm Dig
. 2020 Apr;
112(5):360-366.
PMID: 32338010
Introduction: previous studies have shown that higher infliximab trough levels are associated with favorable short-term and long-term therapeutic outcomes in inflammatory bowel disease. There is a need to determine which...
9.
Rodriguez Gil F, Martinez Crespo J, Garcia Belmonte D, de Prado I, de Prado Serrano R
Gastroenterol Hepatol
. 2009 Jun;
32(8):584-5.
PMID: 19523718
No abstract available.
10.
Moran Sanchez S, Rincon Fuentes J, de Prado I, Martinez Madrid O, Candel Erenas J, Garcia Perez B, et al.
Gastroenterol Hepatol
. 2007 Oct;
30(8):457-60.
PMID: 17949612
Tuberculosis is a common infection worldwide. In developed countries, the incidence of this disease was low until a few years ago. However, due to the rise in immigration and HIV...